Snider Financial Group Seagen Inc. Transaction History

Snider Financial Group

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 25, 2023	BUY	$191.51 - $216.16 $29,301 - $33,072	153 Added 1.29%	12,011 $2.55 Million
Q2 2023 Jul 19, 2023	BUY	$187.64 - $206.25 $26,457 - $29,081	141 Added 1.2%	11,858 $2.28 Million
Q1 2023 Apr 10, 2023	SELL	$127.59 - $203.08 $371,286 - $590,962	-2,910 Reduced 19.89%	11,717 $2.37 Million
Q4 2022 Feb 10, 2023	BUY	$117.37 - $139.17 $49,882 - $59,147	425 Added 2.99%	14,627 $1.88 Million
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $13,256 - $17,650	-98 Reduced 0.69%	14,202 $1.98 Million

Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $358,093 - $590,175	-3,291 Reduced 18.71%	14,300 $2.53 Million
Q1 2022 May 13, 2022	BUY	$119.61 - $157.85 $488,128 - $644,185	4,081 Added 30.21%	17,591 $2.53 Million
Q4 2021 Jan 18, 2022	BUY	$142.57 - $190.86 $144,565 - $193,532	1,014 Added 8.11%	13,510 $2.13 Million
Q3 2021 Nov 05, 2021	BUY	$142.45 - $169.82 $60,113 - $71,664	422 Added 3.5%	12,496 $2.2 Million
Q2 2021 Aug 31, 2021	BUY	$135.08 - $161.1 $1.63 Million - $1.95 Million	12,074 New	12,074 $1.77 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Snider Financial Group, based on Form 13F filings with the SEC.

Stay updated on Snider Financial Group with notifications on news.